Daclizumab a novel corticosteroid-sparing therapy for asthma?

Abstract

Background: In asthma, inhaled corticosteroids are not always able to maintain an optimal therapeutic control despite being used at high doses; other anti-inflammatory therapies are needed. Several such therapies, including daclizumab, are currently under evaluation.

Objective: To discuss the results of study on daclizumab in asthma patients.

Methods: Analysis of efficacy and safety data from a randomised placebo-controlled study performed in patients with moderate to severe asthma and suboptimal control under high doses of inhaled corticosteroids.

Conclusions: Daclizumab demonstrated significant efficacy and its further clinical evaluation in asthma is supported by these results.